Rubra Medicaments Share Price

Rubra Medicaments

CMP as on07-May-22 13:00

₹ 4.30
0 0%

Open

₹ 4.30

Turnover (lac)

Prev. Close

₹ 4.30

Day's Vol (shares)

₹ 2

Day's Range

₹ 4.30
₹ 4.30

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 13-May-2022 - -
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2022 inter alia to consider and approve The Standalone Audited Financial Results of The Company For The Quarter And Year Ended March 31 2022.
Board Meeting - 24-Feb-2022 - -
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/03/2022 inter alia to consider and approve Addition of new object in the main object of the company subject to approval of members and other statutory approval. This is to inform you that the Board of Directors of the Company at its meeting held on Friday, March 4, 2022, inter alia, has considered and approved the following: A. Addition of new object in the main object of the company subject to approval of members and other statutory approval. B. Approved notice, calling of postal ballot for: I. Change in name of the Company to new name. II. Addition of new object in the main object of the company. C. The e-voting period begins on Saturday March 5, 2022 at 10.00 a.m. and ends on Monday, April 4, 2022 at 5.00 p.m. During this period, shareholders of the Company holding shares as on the cut-off date i.e. February 25, 2022, may cast their vote electronically. (Copy of Postal Ballot notice Enclosed) (As Per BSE Announcement Dated 04.03.2022)
Board Meeting - 02-Feb-2022 - -
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2022 inter alia to consider and approve This is to inform you that a Board Meeting of the Directors of the Company is scheduled to be held on Friday February 11 2022 to discuss and approve the following: 1. Standalone unaudited Financial Result along with limited review report for the Quarter ended December 31 2021. 2. Recommendation for change in name of the Company to new name subject to approval of the members of the Company and other statutory authorities. This is to inform you that the Board of Directors of the Company at its meeting held on Friday, February 11, 2022, inter alia, has considered and approved the following: A. Unaudited Standalone Financial Results along with Limited review report for the quarter ended December 31, 2021 B. Change in name of the Company to new name subject to approval of the members of the Company and other statutory authorities and calling of Members meeting. (As per BSE Announcement Dated on 11/02/2022)
Board Meeting - 01-Nov-2021 - -
Quarterly Results RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2021 ,inter alia, to consider and approve Standalone Unaudited Financial Results along with limited review report, Asset and liability statement and Cash Flow Statement of the Company for the half year ended September 30, 2021. Standalone Unaudited Financial Results along with limited review report, Asset and liability statement and Cash Flow Statement of the Company for the quarter and half year ended September 30, 2021 (As Per BSE Announcement Dated 11.11.2021)
Board Meeting - 02-Aug-2021 - -
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2021 ,inter alia, to consider and approve 1. Standalone Unaudited Financial Results along with limited review report of the Company for the quarter ended June 30, 2021. 2. To fix the dates of Book Closure for Annual General Meeting. 3. To decide the time, venue and date of Annual General Meeting. To Consider and approved Unaudited Standalone Financial Results along with limited review report for the quarter ended June 30, 2021 (As Per BSE Announcement dated on 13.08.2021)
Board Meeting - 15-Jun-2021 - -
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/06/2021 ,inter alia, to consider and approve the Standalone Audited Financial Results of the Company for the quarter and year ended March 31, 2021 To considered and approved the Audited Standalone Financial Results for the year ended March 31, 2021 (As per BSE Announcement Dated on 29/06/2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity